ConductScience.org, home

Trial · NCT05725018

Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimarySafety Endpoint (number of treatment-related and treatment-emergent adverse events (AEs) and serious adverse events (SAEs)6 months
The number of treatment-related and treatment-emergent adverse events (TEAEs), treatment-emergent wound adverse events (TEWAEs), and serious adverse events (SAEs), including systemic and wound-specific adverse events.
PrimarySafety Endpoint (number of patients and wounds that have an infection or any related adverse event.)6 monthsThe number of patients and wounds that have an infection or any related adverse event (AE).
PrimarySafety Endpoint (number of patients and wounds that result in hospitalization (serious adverse event )6 monthsThe number of patients and wounds that result in hospitalization (SAE).
PrimarySafety Endpoint (Incidence of squamous cell carcinoma)6 monthsThe incidence of squamous cell carcinoma (SCC).
PrimarySafety Endpoint RCR status6 monthsReplication-competent retrovirus (RCR) status.
OtherProportion of RDEB wounds with ≥50%, ≥75%, and complete6 months
Proportion of RDEB wounds with ≥50%, ≥75%, and complete (i.e., re epithelialization with no drainage or erosion and presence of only minor crusting) healing at Weeks 12 and 24, as determined by direct Investigator assessment.
OtherExtent of pain reduction assessed by the Wong-Baker FACES scale6 monthsExtent of pain reduction assessed by the Wong-Baker FACES scale (for patients ages ≥6 years old) at Weeks 8, 12, and 24.
OtherLongitudinal change in scores of Worst Itch Numeric Rating Scale6 monthsLongitudinal change in scores of Worst Itch Numeric Rating Scale (WI-NRS; for patients ages ≥6 years old) scores assessed at Weeks 8, 12, and 24
OtherLongitudinal change of Zarit Burden Interview Short Form6 monthsLongitudinal change of Zarit Burden Interview Short Form (ZBI-12) for caregiver scores related to wound care, assessed at Weeks 12 and 24 (for all ages).
OtherChange in Quality of Life in Epidermolysis Bullosa6 months
Change in Quality of Life in Epidermolysis Bullosa (QOLEB) scores assessed at Week 24 compared with pretreatment Baseline scores (completed by patients ≥11 years old or with guidance for patients 8 to 10 years old). If patient is \<8 years old, QOLEB should be completed by a legal guardian.
OtherChange in Caregiver Global Impression of Pain6 monthsChange in Caregiver Global Impression of Pain (CrGI-Pain) scores assessed at Weeks 8, 12, and 24 compared with pretreatment Baseline (for all ages).
OtherComparison of how non-collagenous region 1 of the collagen VII molecule6 monthsComparison of how non-collagenous region 1 of the collagen VII molecule (NC1) status relates to wound healing and safety profile (if applicable).
OtherComparison of how circulating C7 antibody status relates to wound healing and safety profile6 monthsComparison of how circulating C7 antibody status relates to wound healing and safety profile (if applicable).

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05725018/registered